Sunesis at sector perform, $7 price target by RBC

Sunesis Pharmaceuticals, Inc. was given a sector perform, speculative risk, rating and a $7 price target by RBC Capital Markets analyst Jason Kantor. The analyst is encouraged by early signs of efficacy in an ongoing phase 1 trial of SNS-595 in advanced leukemia patients. Two phase 2 trials in lung cancer are ongoing with results expected in 2007. Sunesis' diversified cancer pipeline includes a second clinical candidate, SNS-032, in phase 1/ 2 development as well as a preclinical aurora kinase inhibitor. Shares of the South San Francisco, Calif.-based clinical-stage biopharmaceutical company were up 20 cents, or 4.30%, at $4.85. (Nasdaq: SNSS)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.